Inactive Instrument

Highlights COSMO Pharmaceuticals SA Swiss Exchange

Equities

LU1202320294

End-of-day quote Swiss Exchange Other stock markets
- ^CHF	-

06-18	Switzerland's Cosmo Pharmaceuticals Receives Drug Registration Certificate for Lumeblue in China	MT
04-26	Cosmo Pharmaceuticals N.V. Announces Executive Changes at the Upcoming Annual General Meeting on 24 May 2024	CI

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Cosmo Pharmaceuticals Swings to Loss in FY23; Revenue Down	06-03	MT
Cosmo Pharmaceuticals N.V. Proposes Dividend Payment for 2024	03-20	CI
Cosmo Pharmaceuticals N.V. Provides Earnings Guidance for the Year 2024 and Revenue Guidance for 2025	03-20	CI
Cosmo Pharmaceuticals' FY23 Profit, Revenue Drops	03-20	MT
Cosmo Pharmaceuticals N.V. Reports Earnings Results for the Full Year Ended December 31, 2023	03-19	CI
Medtronic Expands Partnership With Cosmo Pharmaceuticals Unit	12-11	MT
Cosmo Pharmaceuticals, Medtronic to Boost AI Focus in Expanded Partnership	12-11	MT
Cosmo Pharmaceuticals Redeems EUR175 Million of Bonds due 2023	12-06	MT
Global markets live: Nvidia, Chevron, FedEx, Roche, PepsiCo...	23-10-10
Cosmo Pharmaceuticals Files Marketing Authorization Application in Europe for Topical Acne Treatment	23-10-10	MT
Cosmo Pharmaceuticals Licenses Acne Treatment Winlevi to Hikma in Middle East, North Africa	23-10-02	MT
Cosmo Pharmaceuticals Signs Distribution, Licensing Deals with Glenmark for Acne Cream in Europe, South Africa	23-09-27	MT
Cosmo Pharmaceuticals N.V. and Glenmark Specialty S.A. Announce the Signing of Distribution and License Agreements for Winlevi® in Europe and South Africa	23-09-27	CI
Cosmo Pharmaceuticals Signs License Deal With Adalvo for Rifamycin	23-09-04	MT
Cosmo Pharmaceuticals Cancels Dr. Falk Pharma's EU License for Travelers' Diarrhea Drug	23-09-04	MT
Cosmo Pharmaceuticals N.V. Reiterates Earnings Guidance for the Year 2023	23-07-26	CI
Cosmo Pharmaceuticals N.V. Reports Earnings Results for the Half Year Ended June 30, 2023	23-07-26	CI
Cosmo Pharmaceuticals Posts Lower H1 Post-tax Profit; Revenue Rises	23-07-26	MT
Cosmo Pharmaceuticals N.V. Announces the Beginning of the Phase III Trials in Men for the Treatment of Androgenetic Alopecia	23-06-29	CI
Cosmo Pharmaceuticals Wins Japanese Nod For Ulcerative Colitis Drug	23-06-28	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights COSMO Pharmaceuticals SA Swiss Exchange

Equities

LU1202320294

Highlights

Filters